Navigation Links
Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference
Date:3/12/2009

BILLERICA, Mass., March 12 /PRNewswire/ -- Seahorse Bioscience, Inc., leader in the real-time measurement of cellular bioenergetics, announced today that the XF96 Extracellular Flux Analyzer, the first analytical instrument for the kinetic measure of mitochondrial oxygen consumption and cytoplasmic glycolysis in a 96-well microplate, was selected as the Best New Product for Drug Discovery Assays & Kits by researchers at the Molecular Medicine Tri-Conference in San Francisco.

"The XF96 Analyzer has revolutionized the way we approach toxicity screening," said Yvonne Will of Pfizer's Compound Safety Prediction Group, who spoke about mitochondrial toxicity at the conference and one of the first users of the XF96. "Since getting the high throughput capabilities of the XF96 Analyzer, we routinely generate 6 point cellular bioenergetic EC50's on our drug candidates - something that just wasn't possible before."

XF Analyzers enable researchers to simultaneously measure the two major energy-producing pathways of the cell in real-time, delivering easy-to-use, information-rich bioenergetic assays to study and develop treatments for obesity, diabetes, ageing and cancer, and to screen for mitochondrial toxicity.

The XF96 Analyzer offers the distinct advantage of making it possible to perform these complex bioenergetic assays in a 96-well microplate. XF Analyzers replace Clark-type electrodes, oxygen or pH sensitive dyes, and radiolabeled substrates.

"Prior to the introduction of our XF instruments the standard method for oxygen measurements was using a Clark electrode, invented in 1953, and a flask of millions of cells," stated Steve Chomicz, Seahorse VP Sales & Marketing. "The XF is the new standard and this award mirrors the positive response we experience everyday from researchers struggling to measure cellular bioenergetics. Seahorse and the XF development team are delighted with CHI's recognition of the value of the XF platform."

About Seahorse Bioscience

Seahorse XF instruments have become the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, please visit http://www.seahorsebio.com.

    Media Contact: Cynthia Egan
    Phone: 978.671.1610


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
2. Extracellular protein sensitizes ovarian cancer cells to chemotherapy
3. Abaxis Launches The VetScan(R) HM5 a State-of-the-Art 5-Part Differential Veterinary Hematology Analyzer
4. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
5. New Gas Analyzer Measures Two Gases at Once!
6. Sysmex America Receives FDA Clearance for XE-5000(TM) Hematology Analyzer
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
9. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
10. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
11. CareAnalyzer From DST Health Solutions Helps Health Plans Improve Care Management and Quality for Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, ... 8th Day Software and Consulting, LLC , and named ... 8th Day Software, based in Tennessee , ... 8th Day expands EnvoyHealth,s service offerings for health care ... "In an interoperable ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology: